<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D50C3B58-FF77-4BB1-B965-C0CF5BDF7F8B"><gtr:id>D50C3B58-FF77-4BB1-B965-C0CF5BDF7F8B</gtr:id><gtr:name>Italian Institute of Technology (Istituto Italiano di Tecnologia IIT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Child Health</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D50C3B58-FF77-4BB1-B965-C0CF5BDF7F8B"><gtr:id>D50C3B58-FF77-4BB1-B965-C0CF5BDF7F8B</gtr:id><gtr:name>Italian Institute of Technology (Istituto Italiano di Tecnologia IIT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/468F2797-5295-4912-BDED-8F3402CE246A"><gtr:id>468F2797-5295-4912-BDED-8F3402CE246A</gtr:id><gtr:name>New York University</gtr:name><gtr:address><gtr:line1>7 East 12th Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CCB924E1-3212-4C04-8132-7367F80BA047"><gtr:id>CCB924E1-3212-4C04-8132-7367F80BA047</gtr:id><gtr:firstName>Joanne</gtr:firstName><gtr:surname>Ng</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK02342X%2F1"><gtr:id>996FA7FF-E912-4821-B1F6-3D3DB5D8CF0F</gtr:id><gtr:title>A gene therapy approach to childhood parkinsonism</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K02342X/1</gtr:grantReference><gtr:abstractText>Infantile parkinsonism is a severe progressive disease that is incurable and children affected die in adolescence. It begins in infancy with features similar to adult Parkinsons disease with severe difficulties with movement and unsteadiness. The faulty gene that causes this condition has been identified and its function understood. This makes it a potential condition that could be treated by gene therapy as no other treatments have worked or helped so far.

The faulty gene is responsible for producing proteins involved in transporting a chemical in the brain that controls movements. In this condition the protein does not work effectively leading the severe movement difficulties and death in adolescence.

I will research ways to deliver a normal form of the gene to a mouse model with the disease. An animal study is required as it is not safe to study these techniques directly in humans. There is a mouse model that simulates the human from of infantile parkinsonism condition well. This mouse does not produce any of form of the protein and shows all the signs with movement difficulties and reduced longevity seen in the human form of the condition. 

We would aim to give the mouse the normal gene through an injection into the blood stream. We would assess for improvements in movements, weight gain and lifespan to assess whether the gene treatment has helped. We would assess carefully for side effects and ability for the gene treatment to reach the brain in the mouse, the area where we want the treatment to work.

We would study the mice to see if the normal function of the gene is restored and would see this with improvements in movements and longevity of the mice. We would assess the mice to ensure the gene treatment is safe and effective and assess the best age to give the treatment and ideal dosage. Further studies of the effects of the gene treatment will be performed by assessing tissue samples from the mice. Successful gene therapy study in mice will help us to proceed to establish future studies in humans. In the future these techniques may also be applicable to other incurable childhood brain disorders.</gtr:abstractText><gtr:technicalSummary>Dopamine transporter deficiency syndrome (DTDS) is a newly recognised autosomal recessive neurotransmitter disorder clinically characterised by progressive infantile parkinsonism dystonia. It is caused by loss-of-function mutations in the SLC6A3 gene that encodes for the dopamine transporter (DAT).This progressive condition does not respond to medical or surgical treatments leading to early death.

Gene therapy is increasingly being considered as a realistic treatment option for human disorders including a number of successful clinical gene therapy trials. Indeed there has been a recent clinical gene therapy trial showing positive results in children with AADC deficiency. This is another devastating genetic neurotransmitter disorder lacking in medical treatment. This study demonstrated improvement in oculogyric crisis and motor abilities in all children treated and provides impetus to study potential gene therapy in DTDS.

A proof of concept study would be required to describe expression of transgene delivery and restoration of DAT expression in the first instance. We aim to develop a gene therapy strategy in the knockout mouse model of DTDS. We hypothesise that by inserting human DAT through gene transfer to the DAT-KO mouse model will restore gene function and DAT expression and function. 

The key aims of the study are to: 

1. Establish a DAT-KO mouse colony at UCL
2. Develop a safe and efficient vector for transgene delivery to the central nervous system in DAT- KO mouse model
3. Demonstrate efficacy through restoration or augmentation of DAT expression through locomotor phenotyping and tissue histological study.
4. Establish optimal time of administration of gene transfer
5. Establish optimal dosage and correlate dosage effects

In the longer term this study would underpin future translation to clinical trials of gene therapy in DTDS. The expertise gained may also be applicable to other untreatable childhood neurological diseases.</gtr:technicalSummary><gtr:potentialImpactText>Through this study we would aim that gene vector design, safety and efficacy, optimal method, dosing and timing of gene transfer therapy will have been established in the DAT KO mouse. We would hope that successful gene therapy in a murine model may lead to further translational study. 

With Dr Kurian's complimentary work in cell line model and Professor Thrasher's expertise in translating animal study to clinical trial we would hope to use the data from this project to underpin future clinical study. The long term goal of this research may lead to the development of suitable vector delivery systems to be used in DTDS patients trial in patients within a 10 years time-line. 

The findings of this study and future application are especially beneficial and relevant to children with DTDS. It will be of relevance to other children with neurotransmitter disorders, movement disorders. In addition, techniques developed from this study may be applicable more widely for research in to gene transfer therapeutic options for other related movement disorders and other untreatable childhood neurological disorders. 

Dr Kurian is an established expert clinician in childhood movement disorders and has access to recruit future children with DTDS for study. As Great Ormond Street houses the National Neurotransmitter laboratory in the UK, all children found to have a characteristic neurotransmitter profile associated with DTDS will be easily identified for consideration for clinical study and recruitment for further study through Dr Kurian's established collaboration with Professor Simon Heales, Clinical Chemistry unit, Institute Child Health and Great Ormond Street Hospital. 

The findings of this research will be disseminated through relevant scientific meetings and publication in high impact factor journals that would lead to further national and international awareness of this condition and awareness of our collaborative's long term aims of translational research towards future clinical trials. This will lead to further collaboration with other groups which is often required in rare diseases and gene therapy trials. 

In addition the members of this collaborative group are already sit on the scientific boards of relevant international family and patientsgroups for children with Neurotransmitter disorders (AADC Trust and Pediatric Neurotransmitter Disorder) who would also be informed of the findings of this work. This again will enhance all future collaboration at an international level to bringing this work towards clinical trial and ensuring ths research of the highest standard is undertaken.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>281271</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Marc Caron</gtr:description><gtr:id>D4C65585-E19A-412C-95C1-501D08D500DD</gtr:id><gtr:impact>The expertise from Marc Caron and his laboratory enabled the rapid and successful establishment of the DAT-KO transgenic colony at UCL</gtr:impact><gtr:outcomeId>54624472b0a3e5.02174743-1</gtr:outcomeId><gtr:partnerContribution>Marc Caron developed the DAT-KO mouse and delivered a personal seminar on this model to our group. He provides expertise in this model to support this project.</gtr:partnerContribution><gtr:piContribution>We have delineated the clinical phenotypes and genotypes of dopamine transporter deficiency leading to greater understanding of the animal model developed prior to the clinical disease identification.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Italian Institute of Technology (Istituto Italiano di Tecnologia IIT)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Raul Gainetdinov</gtr:description><gtr:id>97AC576A-AC1F-466B-AD72-DEC94D0F2F12</gtr:id><gtr:impact>DAT-KO colony established at UCL</gtr:impact><gtr:outcomeId>54624331e44db6.41798587-1</gtr:outcomeId><gtr:partnerContribution>Establish colony at UCL as model of childhood dopamine transporter deficiency syndrome for proof of concept study of gene therapy.</gtr:partnerContribution><gtr:piContribution>Professor Gainetdinov kindly provided the DAT-KO mouse to enable a colony to be established at UCL for this fellowship.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy</gtr:department><gtr:description>Gene therapy for neurological disease Dr Ahad Rahim</gtr:description><gtr:id>5CEE95C7-5C77-4A31-A065-207091BC1DD8</gtr:id><gtr:impact>Joint grant applications leading towards preclinical gene therapy study of brain iron disorders</gtr:impact><gtr:outcomeId>5640c118435f50.89887913-1</gtr:outcomeId><gtr:partnerContribution>Refinement of neuronal gene therapy tranduction approaches for both neurological and multisystem neurological diseases</gtr:partnerContribution><gtr:piContribution>Joint experience in gene therapy approaches to neurological diseases</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Clinical and Experimental Epilepsy</gtr:department><gtr:description>Dr Gabriele Lignani</gtr:description><gtr:id>AF496E3F-42BB-44AC-AF43-76271AC464C4</gtr:id><gtr:impact>These data will be compiled for publication for gene therapy approach for DAT deficiency.</gtr:impact><gtr:outcomeId>581877f4e5e709.66817850-1</gtr:outcomeId><gtr:partnerContribution>Dr Llignany performed patch clamp electrophysiology and showed differences between wildtype and DAT knockout animals in neuronal firing rates.
The DAT knockout animals treated with gene therapy showed the neuronal firing rate was restored to wildtype firing patters.</gtr:partnerContribution><gtr:piContribution>Further analysis of the gene therapy in DAT knock mouse model was possible using ex vivo electrophysiology. 
DAT knockout mice treated with gene therapy and their litter mate controls (untreated knockouts and wildtype mice) were collected for analysis.
Brain slices were prepared for patch clamp electrophysiology by Dr Lignani.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Simon Heales</gtr:description><gtr:id>A8284511-41F3-4DB9-878A-88C61C932F25</gtr:id><gtr:impact>Collaboration between clinicians, clinical biochemists and gene therapy groups for biomarker analysis in murine models of human disease.</gtr:impact><gtr:outcomeId>5463ddc630a230.97072971-1</gtr:outcomeId><gtr:partnerContribution>Able to link CSF neurotransmitter patients and DAT=KO mouse model of DTDS deficiency.</gtr:partnerContribution><gtr:piContribution>Clinical input into the neurotransmitter analysis of patients referred to Professor Heales Neurotransmitter laboratory</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>New York University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Maarten Reith</gtr:description><gtr:id>4FC7B24D-4701-4ECA-B782-4EDE8962F2C7</gtr:id><gtr:impact>Original publication in Brain 2014: 137; 1107-1119 Dopamine transporter deficiency syndrome:
phenotypic spectrum from infancy to adulthood</gtr:impact><gtr:outcomeId>5462461c67c097.60760223-1</gtr:outcomeId><gtr:partnerContribution>Maarten Reith's group provide expertise and support in functional modelling of novel genotypes in the dopamine transporter. 
His group provided the plasmids initially used in cloning of gene therapy constructs.</gtr:partnerContribution><gtr:piContribution>We identify novel genotypes in DAT deficiency syndrome for further function study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>AADC deficiency research trust conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4639CF9B-3B9E-4524-9235-30967A61D03C</gtr:id><gtr:impact>The conference combines patients and families with AADC deficiency and experts in neurotransmitter disease and gene therapy.
The conference focussed on the launch for gene therapy clinical trial for this disease and also patients describing their main clinical difficulties.

After this conference further efforts for fundraising and applications for a European site for gene therapy clinical trial were further discussed</gtr:impact><gtr:outcomeId>5640c63386d8f7.10715297</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit  Gracious Heart Foundation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9E0A979A-7217-4E04-BAF0-DDF14B235185</gtr:id><gtr:impact>The talk lead to further questions from the public and supporters of the charity. Also lead to other medical research charities contacting our group with further funding proposals to support our studies.

The talk raised awareness of alternative diagnosis for cerebral palsy. Many practitioners involved in conductive education for children with cerebral palsy were present and keen to be aware of alternative diagnoses and treatments.</gtr:impact><gtr:outcomeId>5462302ab52a57.10416742</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.graciousheart.co.uk</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>NBIA Disorders Association</gtr:fundingOrg><gtr:id>4B244FF7-CE20-4723-92A8-7C4C039BD983</gtr:id><gtr:outcomeId>54622d73ca2142.68915847</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Gracious Heart Charity Foundation</gtr:fundingOrg><gtr:id>0AE80EF3-ABC1-47B2-9D24-BE247600D5B5</gtr:id><gtr:outcomeId>54622dc44c9523.59836813</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GOSHCC Starter Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:fundingOrg><gtr:fundingRef>1PAAE</gtr:fundingRef><gtr:id>EFE3C7EC-7FE5-4D33-9B8E-1474CAB09C64</gtr:id><gtr:outcomeId>54623ce61e2880.21562649</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Children referred to Dr Kurian Childhood movement disorder clinic with undiagnosed movement disorders.
Database established to enable grouping of phenotypes to facilitate analysis of whole exome sequencing data.</gtr:description><gtr:id>B964E08F-BC0B-4AA4-97E8-25D95197F607</gtr:id><gtr:impact>Database established to enable grouping of phenotypes to facilitate analysis of whole exome sequencing data.</gtr:impact><gtr:outcomeId>546232b0b90184.16227671</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Database of undiagnosed childhood movement disorders</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Isolation of neurons using magnetically labelled cells and antibodies using MACS brain dissociation and seperation kits.</gtr:description><gtr:id>127C6A06-1BC2-4FF1-A5B1-6CCA4C11C682</gtr:id><gtr:impact>Able to isolate cell lines and perform invitro studies from in vivo tissues that have been treated with gene therapy</gtr:impact><gtr:outcomeId>5640c30ccc6e44.14960927</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MACS cell seperation for Neuronal isolation</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>HPLC analysis of neurotransmitter metabolites in mouse brain homogenates</gtr:description><gtr:id>EBCC8A36-53F5-49FA-9BF1-E982E1EF3CC6</gtr:id><gtr:impact>Reliable biochemical assay for future outcome measure of gene therapy efficacy</gtr:impact><gtr:outcomeId>54623edb9ff3d1.52503250</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Neurotransmitter analysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Immunohistochemistry used to assess marker gene studies in mouse brain transduction.
Immunohistochemistry also used to delineate neurohistopathology in transgenic mouse models of neurological disease</gtr:description><gtr:id>A385972B-5815-45BD-984F-D5BDC1C4CAAD</gtr:id><gtr:impact>Enable marker gene studies for other viral vectors and neurohistopathology in other mouse models.</gtr:impact><gtr:outcomeId>5462322e8b6d00.48322644</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Immunohistochemistry</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Quantification method for protein expression delivered by gene therapy</gtr:description><gtr:id>F2A567A1-8717-4D14-8272-0AB558519B43</gtr:id><gtr:impact>Quantification of protein expression in target organs and off target transduction</gtr:impact><gtr:outcomeId>5640c20feed4c1.42934677</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Elisa</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cloning of transgenes into viral vectors to develop gene therapy vectors.</gtr:description><gtr:id>8A3D368E-6046-47FB-BC8B-6F85E81FBB7F</gtr:id><gtr:impact>Vital for rescue of mouse model of disease for this proof of concept gene therapy model</gtr:impact><gtr:outcomeId>5463dfb6f267a5.65708180</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cloning therapeutic vectors</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Motor behavioural analysis in transgenic mouse colony</gtr:description><gtr:id>7F383E3B-A342-4C0D-BBF8-793EFD2F989D</gtr:id><gtr:impact>Enables standardised outcome measure for future gene therapy efficacy</gtr:impact><gtr:outcomeId>54623f224e4874.90810715</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Behavioural studies of DAT-KO mice</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Establish colony at UCL as model of childhood dopamine transporter deficiency syndrome for proof of concept study of gene therapy.</gtr:description><gtr:id>1E99A440-18C0-4618-919D-3E4BEC44C7BC</gtr:id><gtr:impact>Establish colony at UCL as model of childhood dopamine transporter deficiency syndrome for proof of concept study of gene therapy.</gtr:impact><gtr:outcomeId>546231b18fa517.40190234</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Establishment of DAT-KO mouse colony</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Establishing making of adenoassociated virus production and purification.</gtr:description><gtr:id>6C1592B4-9012-43D8-9560-51D1637D1621</gtr:id><gtr:impact>Enables AAV production within our research group and reduces reliance on other groups</gtr:impact><gtr:outcomeId>54623e6c9f0d40.43111238</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Adeno associated virus preparation</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>CSF analysis of dopaminergic system related proteins in patient CSF.</gtr:description><gtr:id>FF751F20-599A-41EF-AEBA-BDC57826572A</gtr:id><gtr:impact>These observations may demonstrate effects down and upstream of loss of function of dopamine transporter
May be a future method to understand disease mechanism in patients</gtr:impact><gtr:outcomeId>5640c294a80a18.76990934</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Immunoblotting</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Staining of neuronal cultures</gtr:description><gtr:id>DB0A0C70-2916-4778-8946-3768755C35BA</gtr:id><gtr:impact>To demonstrate location of gene therapy expression protein</gtr:impact><gtr:outcomeId>5640c3473f2a87.13555284</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Immunocytochemistry</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4D76B554-B2FE-44F1-AF18-70C307E3D494</gtr:id><gtr:title>Monoamine neurotransmitter disorders--clinical advances and future perspectives.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e7cbcd8fe3fc8006c3fe7b2f558d48a"><gtr:id>6e7cbcd8fe3fc8006c3fe7b2f558d48a</gtr:id><gtr:otherNames>Ng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>5640bf94ef7568.44159203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EE01265-3EDA-4D4C-A3FE-9F96E7C62178</gtr:id><gtr:title>Mutations in a Sibship with Multifocal Polymyoclonus.</gtr:title><gtr:parentPublicationTitle>Tremor and other hyperkinetic movements (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b6b94acd79bf9b7702383a2cfc40f72"><gtr:id>0b6b94acd79bf9b7702383a2cfc40f72</gtr:id><gtr:otherNames>Ngoh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2160-8288</gtr:issn><gtr:outcomeId>5aa7a750d02130.41365160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5DEC588-D638-4B26-A1A0-1266AA2C0268</gtr:id><gtr:title>Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders.</gtr:title><gtr:parentPublicationTitle>Paediatric drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e7cbcd8fe3fc8006c3fe7b2f558d48a"><gtr:id>6e7cbcd8fe3fc8006c3fe7b2f558d48a</gtr:id><gtr:otherNames>Ng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1174-5878</gtr:issn><gtr:outcomeId>54622cb02a9bd2.69984483</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81AD5E74-D4E4-49EA-972F-001C0CF70ABE</gtr:id><gtr:title>What is new for monoamine neurotransmitter disorders?</gtr:title><gtr:parentPublicationTitle>Journal of inherited metabolic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/643f55cc5900ebe6caff07529c126569"><gtr:id>643f55cc5900ebe6caff07529c126569</gtr:id><gtr:otherNames>Marecos C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0141-8955</gtr:issn><gtr:outcomeId>54622c3e1d78c9.07039800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DBD74B4-55D4-4602-98DA-CA0C6A54F60A</gtr:id><gtr:title>Delineation of the movement disorders associated with FOXG1 mutations.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e394df3f2ea9e919ccfad29a6dca34d1"><gtr:id>e394df3f2ea9e919ccfad29a6dca34d1</gtr:id><gtr:otherNames>Papandreou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5a6dce10e71dd8.52385665</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6483E8AA-58BC-4996-8388-2C571ADDEB40</gtr:id><gtr:title>Low CSF 5-HIAA in Myoclonus Dystonia.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfb676b61584161f3525a4a662573280"><gtr:id>bfb676b61584161f3525a4a662573280</gtr:id><gtr:otherNames>Peall KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>5aa7a750a32818.57872400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C67EA53D-D86B-4A6F-8CF7-5FF96FE3B773</gtr:id><gtr:title>Continual conscious bioluminescent imaging in freely moving somatotransgenic mice.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e539d786838b9aaf0be5a6ec3a6cc586"><gtr:id>e539d786838b9aaf0be5a6ec3a6cc586</gtr:id><gtr:otherNames>Karda R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa7a7517e8b14.17376392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AF5C4B6-EDF5-45CC-81EC-63C1F279E66A</gtr:id><gtr:title>Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e7cbcd8fe3fc8006c3fe7b2f558d48a"><gtr:id>6e7cbcd8fe3fc8006c3fe7b2f558d48a</gtr:id><gtr:otherNames>Ng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>54622c3deb6314.11997323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F77947D2-154F-497D-BD0B-47B6886406ED</gtr:id><gtr:title>Perinatal systemic gene delivery using adeno-associated viral vectors.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e539d786838b9aaf0be5a6ec3a6cc586"><gtr:id>e539d786838b9aaf0be5a6ec3a6cc586</gtr:id><gtr:otherNames>Karda R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>5640bf53eae8b1.54977379</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB222882-620D-4738-B83C-FD92FFBCE115</gtr:id><gtr:title>encephalopathy: Broadening the phenotype and evaluating treatment and outcome.</gtr:title><gtr:parentPublicationTitle>Neurology. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea6f2aa1a89130823fad3e545a0e4e07"><gtr:id>ea6f2aa1a89130823fad3e545a0e4e07</gtr:id><gtr:otherNames>Danti FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2376-7839</gtr:issn><gtr:outcomeId>5aa7a7505ce0e9.81691416</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K02342X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>